Clinical trial on a promising new treatment for AMD has kicked off last month in Princeton, New Jersey. Pharmaceutical company Ophthotech enrolled the first patient to test E10030 - an anti-PDGF aptamer, in combination with an anti-VEGF agent.
Pre-clinical trials showed that E10030 has the potential to regress abnormal blood vessels in AMD. The current treatments like Macugen - which rely only on anti-VEGF therapy - are unable to do that.
"We believe E10030 holds great promise for enhancing the visual outcome for patients with AMD," said Samir Patel, Ophthotech's president and CEO.
Pre-clinical trials showed that E10030 has the potential to regress abnormal blood vessels in AMD. The current treatments like Macugen - which rely only on anti-VEGF therapy - are unable to do that.
"We believe E10030 holds great promise for enhancing the visual outcome for patients with AMD," said Samir Patel, Ophthotech's president and CEO.
No comments:
Post a Comment